Trial Profile

A phase III trial of Peanut Sublingual Immunotherapy (SLIT) Tablet

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peanut allergy immunotherapy-ALK Abello (Primary)
Indications Peanut hypersensitivity
Focus Therapeutic Use

Most Recent Events

24 Apr 2026 New trial record
20 Apr 2026 According to a ALK-Abello media release, the company plans for phase 3 development of the peanut tablet, which is expected to be initiated towards the end of 2026, pending dialogue with the healthcare authorities on the final trial design.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com